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Alpha-lipoic acid is a naturally occurring substance, essential for the function of different enzymes that take part in
mitochondria’s oxidative metabolism. It is believed that alpha-lipoic acid or its reduced form, dihydrolipoic acid have
many biochemical functions acting as biological antioxidants, as metal chelators, reducers of the oxidized forms of
other antioxidant agents such as vitamin C and E, and modulator of the signaling transduction of several pathways.
These above-mentioned actions have been shown in experimental studies emphasizing the use of alpha-lipoic acid
as a potential therapeutic agent for many chronic diseases with great epidemiological as well economic and social
impact such as brain diseases and cognitive dysfunctions like Alzheimer disease, obesity, nonalcoholic fatty liver
disease, burning mouth syndrome, cardiovascular disease, hypertension, some types of cancer, glaucoma and
osteoporosis. Many conflicting data have been found concerning the clinical use of alpha-lipoic acid in the treatment
of diabetes and of diabetes-related chronic complications such as retinopathy, nephropathy, neuropathy, wound
healing and diabetic cardiovascular autonomic neuropathy. The most frequent clinical condition in which alpha-lipoic
acid has been studied was in the management of diabetic peripheral neuropathy in patients with type 1 as well type 2
diabetes. Considering that oxidative stress, a imbalance between pro and antioxidants with excessive production of
reactive oxygen species, is a factor in the development of many diseases and that alpha-lipoic acid, a natural thiol
antioxidant, has been shown to have beneficial effects on oxidative stress parameters in various tissues we wrote this
article in order to make an up-to-date review of current thinking regarding alpha-lipoic acid and its use as an
antioxidant drug therapy for a myriad of diseases that could have potential benefits from its use.
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Alpha-lipoic acid (ALA) also known as thioctic acid
(TA) and 1,2 dithiolane −3-pentanoic acid, is a naturally
occurring substance, that is essential for the function of
different enzymes of oxidative metabolism [1-3]. ALA
was discovered in 1937 by Snell [4] but only in 1951 it
was isolated by Reed [5]. The first clinical use of ALA
has been described in Germany in 1959 for the treatment
of acute poisoning with amanita phalloides commonly
known as death cap [from mushrooms] a deadly poison
widely distributed in Europe Moreover, soon after, the* Correspondence: mariliabgomes@gmail.com
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article, unless otherwise stated.same authors described its utility in treating neuropathic
complaints [6]. Nowadays it is believed that ALA or its
reduced form, dihydrolipoic acid (DHLA) have many
biochemical functions acting as biological antioxidants,
as metal chelators, reducing the oxidized forms of other
antioxidant agents such as vitamin C and E and glutathi-
one (GSH), and modulating the signaling transduction of
several pathways, like insulin and nuclear factor kappa B
(NFkB) [1]. ALA has also shown to improve endothelial
dysfunction [7] and to reduce oxidative stress post exer-
cise training [8]; it also protects against the development
of atherosclerosis and inhibits the progression of an
already established atherosclerosis plaque [9,10]. These
above-mentioned actions have emphasized the use of
ALA as a potential therapeutic agent for many chronic
diseases with great epidemiological as well economic andCentral Ltd. This is an Open Access article distributed under the terms of the
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plications [11,12], hypertension [13], Alzheimer’s disease
(AD) [14], Down syndrome [15], cognitive dysfunction
and some types of cancer [16]. Currently the use of ALA
as a dietary supplement is growing in many aspects of
medical and nutritional management of patients.
Considering the pleiotropic actions of ALA or DHLA in
so many different organs and systems, in many different
ways, this review has the objective to improve the clinical
and biochemical understanding of its potential use in
routine clinical care for a large spectrum of pathologies.
Synthesis, biochemical properties, absorption and
bioavailability
ALA is commonly found in dietary components such as
vegetables (spinach, broccoli, tomato) and meats, mainly
viscera and also in many dietary supplements. ALA can be
also synthesized through enzymatic reactions in plants and
animals’ mitochondria from octanoic acid and cysteine (as
a sulfur donor) [17,18]. As a sulfur containing substance,
ALA is considered a thiol compound. Mammalian cells can
synthesize ALA through the action of mitochondria lipoic
acid synthase (LASY) which can be down-regulated in
different clinical conditions [18].
ALA exists in two enantiomeric (optical isomers) forms,
R and S, (Figure 1) being the R isoform an essential cofactor
for mitochondrial enzymes of oxidative metabolism since
it is joined in amide linkage to €-amino group of lysine
residues (lipoamide) [17]. The following enzymes use
R-ALA as a cofactor: pyruvate dehydrogenase (PDH),Figure 1 Enantiomers (R and S) of lipoic acid.branched chain α-keto-acid dehydrogenase (KDH) and
α-ketoglutarate dehydrogenase (KGDH) [18,19]. Pyruvate
dehydrogenase is a multienzyme complex, composed by
three enzymes, which catalyze in three steps the irrevers-
ible oxidative decarboxylation of pyruvate into acetyl
coenzyme A (acetyl-CoA), which is a component of the
citric acid cycle [19]. The other above-mentioned enzymes
also catalyze the oxidative decarboxylation of other
α-keto-acid such as α-ketoglutarate, valine, leucine, isoleu-
cine. R-ALA is also a cofactor of glycine cleavage system
which degrades glycine into pyruvate [20].
The absorption and bioavailability of ALA have been
studied mainly from dietary supplements where ALA
exists as an admixture of R-ALA and S-ALA. In general,
the absolute bioavailability of both ennatiomers is not
greater than 40% which decreases with food intake [12].
Therefore, ALA must be taken 30 min before meals.
Some experimental studies have shown that R-ALA has
greater biopotency in several metabolic pathways com-
pared to S-ALA [21].
After oral intake, ALA is absorbed by the gastrointes-
tinal tract and is transported to different organs such as
brain because it has the potential of freely cross the
blood–brain barrier [3]. Independently of the original
sources (diet or nutritional supplements) ALA is reduced
to DHLA and metabolized in the liver in different metab-
olites like bisnorlipoate and, tetranorlipoate, and has renal
excretion.
So far, some systems have been associated with the
cellular transport of ALA like sodium dependent trans-
port, a transmembrane protein which is produced by the
SLC5A6 gene that also translocates other vitamins and
cofactors. Both transporters are also responsible for ALA
intestinal uptake [22].
Antioxidant properties
ALA and its reduced form DHLA, are considered powerful
natural antioxidant agents with a scavenging capacity for
many reactive oxygen species [23,24]. The chemical struc-
ture of both compounds is showed in Figure 2. It is import-
ant to note that there is no agreement about the specific
scavenging capacity of each form [23-31]. Although it is
beyond of the scope of this review, for instances it was
described a different scavenging ability of ALA and DHLA
on aqueous and membrane phase of an experimental study
which means that the environment could be an important
factor for determining its scavenging capacity (24). A sum-
mary of these data are presented in Table 1. ALA/DHLA
have some important advantages over other antioxidant
agents such as vitamin E and C, because they have amphi-
philic properties that confer their antioxidant actions in the
membrane as well as in the cytosol [23].
ALA/DHLA can also regenerate other antioxidant
substances such as vitamin C, vitamin E and the ratio of
Figure 2 Chemical structure of alpha lipoic acid (ALA) and its reduced from dihydrolipoic acid (DHLA).
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one is a sulfur tripeptide containing glutamate, cysteine
and glycine [32]. Their biosynthesis depend on substrate
availability (cysteine), which is enhanced by ALA/DHLA
which convert cystine into cysteine and also through
gene expression [12]. Considering the latter action, ALA/
DHLA is an activator/inducer of translocation of nuclear
factor erythroid 2-related factor (Nrf2) to the nucleus
for regulation of antioxidant gene expression [33]. GSH
which has also a connection with circadian rythms, has
many functions over different intracellular processes
like ageing, oxidative balance and detoxification of many
pollutants [34].
A pro-oxidant effect of ALA is also described in ex-
perimental studies, but it is generally observed at higher
concentrations than the usual plasmatic concentration
observed after oral or intravenous infusion of ALA foundTable 1 Antioxidant action of ALA and DHLA upon
reactive oxygen species and references
Reactive oxygen species ALA DHLA
Hydrogen peroxide Yes (12) Yes (12)
(H2O2) No (23) No (23)
Superoxide
(O2





SInglet oxygen Yes (12,29) Yes (29)
(O2 *) No (24)
Peroxynitrite Yes (12,25) Yes 12,(25)
(ONOO−)
Nitric oxide radical Yes Yes (12)
(NO) (12, 26) No (26)
Hypochlous acid Yes (23, 24, 31) Yes (31)
(HOCL)
Peroxyl radical Yes (23) Yes (23, 30)
(HO2..) No (30)in human studies [35,36]. So far, the pro-oxidant action of
ALA/DHLA is not fully understood but could be related
to different direct or indirect reactions [37] such as
oxidation of DHLA by ubisemiquinone [36], to the
maintenance of NrF2 into the cytosol through a linkage
to Keap1 protein, resulting in the inhibition of the tran-
scription of cytoprotective genes which include many
antioxidant genes [38,39] or to an ubiquination of Nrf2
in a Keap1-dependent action [38].
Metal chelator properties
Chelation is a powerful function for most living species.
A chelator compound has an important function in most
systems because it can counteract agents which have a
potential oxidant action. Although chelation therapy plays
a prominent role in the clinical treatment of metal in-
toxication, its use in the treatment of some diseases
such as DM, cardiovascular and neurodegenerative
entities albeit controversial have been subject to an ex-
tensive discussion [40].
ALA/DHLA are considered as chelator compounds
because they are able to chelate divalent transient metal
ions both in vivo and in vitro but by different mechanisms
of action [41-43]. LA chelates mostly the Mn 2+, Cu 2+,
Pb 2+ and Zn 2+. In addition to the previously mentioned
ions, DHLA is also able to chelate Hg 2+ and Fe 3+. Both
iron and cupper are recognized as mediators for the pro-
duction of reactive oxygen species. Moreover, the actions
of ALA/DHLA as chelating compounds do not cause
metal depletion.
Action upon transduction signaling systems
Insulin pathway
ALA has many actions in the insulin metabolic pathways,
glucose uptake and glycogen synthesis with some differ-
ences between both isomers. In vitro studies have shown
that R-ALA increases the translocation of GLUT1 and
GLUT4 to the plasmatic membrane of adipocytes
[21,41-43] and skeletal muscle cells kept in a culture
milieu [42]. Moreover, these events are associated with
enhanced activity of proteins of the insulin signaling
pathway like insulin receptor (IR), insulin receptor sub-
strate 1 (IRS1), Phosphatidylinositide 3-kinase (PI3K) and
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observed when Zucker rats, that are animal models of
insulin resistance, were studied [43]. There is still a
controversy if this action of ALA is totally insulin-
dependent or not [41-43]. Furthermore, in an animal
model of isolated rat muscles ALA inhibited glycogen
synthesis, and action which is considered to have a
pro-oxidant effect [32]. In general the S-ALA did not
show a significant effect upon glucose disposal [41-43].
Nuclear factor kappa B
Nuclear factor kappa B (NFkB) is a transcription factor
which is maintained in an inactive form in the cytosol
because of its capacity in binding to an inhibitor kinase
of NFkB activity, IKK [44]. Oxidative-stress is associated
with hyperglycemia [45-48], and the existence of other
conditions like viruses, some pathogens, and radiation
are supposed to phosphorylate IkB resulting in its deg-
radation, liberation and activation of NFkB which
translocates to the nucleus to induce the transcription
of several molecules related to inflammation, vascular
adhesion and migration of monocytes [44]. ALA inhibits
NFkB probably because of its action on the inhibition of
the degradation of IkB through modulation of upstream
kinases like MAPK [12] or its ability to regenerate vitamin
E resulting in inhibition of protein kinase C which is
also able to phosphorylate IkB [49]. This action of ALA
seems to be independent of its antioxidant action [50].
Several experimental studies in vitro [50] and in vivo in
rats [51] have shown the anti-inflammatory actions of
ALA but few studies have addressed this subject in
humans [52].
Adenosine monophosfatase protein kinase
ALA has some important functions in the activity and
expression of 5' adenosine monophosphate-activated pro-
tein kinase (AMPK) in peripheral tissues and in brain
(hypothalamus). AMPK is considered a multifunctional
protein involved in many intracellular pathways related
to metabolism, stress response, cell cycle and ageing
[53]. Currently, AMPK plays an important role in linking
nutritional factors and cancer and is considered to be a
promising therapeutic target for cancer prevention and
treatment [54].
AMPK is a cellular energy sensor and it is activated by
liver kinase B1 (LKB-1) and Ca/calmodulin dependent
protein kinase (CaMKK). Activation of AMPK results in
down regulation of transcriptional events that promote
synthesis of gluconeogenic enzymes, synthesis of fatty
acids and up regulation of metabolic pathways resulting
in an increased ATP production through glucose and
fatty acids oxidation [54]. Moreover, AMPK can induce
trasnlocation of GLUT4 to plasma membrane independ-
ent of insulin action [54].So far, it is still unknown which is the mechanism that
induces activation of AMPK by ALA in peripheral tissues.
According to one study with myoblast cells culture, ALA
could increase the activation of AMPK indirectly by acti-
vating CaMKK which becomes activated by an increase in
intracellular Ca2+ [55]. The inhibition of CaMKK abolishes
this action [55]. Indeed, these actions of ALA-AMPK
could also increase energy expenditure by increasing
the activity of protein kinase-peroxisome proliferator-
activated receptor-gamma coactivator-1alpha (PGC-
1-alpha) signaling pathway which is responsible for
mitochondrial biogenesis [56]. All the above-mentioned
actions resulting from ALA activating AMPK will cause a
decrease in plasma glucose, an increase in insulin sen-
sitivity and probably weight loss [53]. Recently it was
described an action of ALA upon AMPKK in insulinoma
cells culture and isolated islets of Langerhans which
resulted in a decreased insulin secretion by 25 to 30% at
low (2.8 mmol/L) and high (15 mmmol/L) glucose con-
centrations [57]. This event was observed both with acute
and chronic treatment with ALA. Considering this latter
action, another study showed a protective effect of ALA
upon 2-deoxy-D-ribose induced oxidative damage and
insulin expression in cultured cells and rat islets [58]. This
protective action seems to be related to an increased intra-
cellular GSH concentration. Both studies have brought to
light important informations about the multiple effects of
ALA upon beta cells. The study design, the stimulus and
the concentration of ALA used in the experiments could
have accounted for the different results that have been
found [58].
ALA is also able to modulate the activity of AMPK in
the brain by metabolic stresses that inhibit ATP produc-
tion such as ischemia, hypoxia, glucose deprivation as well
as by oxidative stress [59]. Recent studies of experimental
neuronal models are pointing to AMPK’s possible roles
beyond energy sensing, some reporting brain protective
effects [60], while others reporting detrimental effects
[61]. These discrepancies may be related to the dose of
glucose added in the culture medium.
It has also been found that hypothalamic AMPK is im-
portant in the central regulation of appetite and energy
expenditure and that ALA exerts anti-obesity effects by
suppressing hypothalamic AMPK activity [62]. In this
setting, ALA has an anorexic property and should be a
potential anti-obesity drug [63].
Relationship between the dose of ALA and its
effects in experimental studies
In most experimental studies performed in vitro a wide
range of ALA doses and glucose concentrations were
used, from 10 umol/L to 5 and from 2.0 mmol/L to
15 mmol/L, respectively and a clear dose-dependent re-
sponse was observed [14,16,58-61,64-66]. The majority
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which type of ALA was used: if a racemic admixture of
R-ALA and S-ALA, only R-ALA or only S-ALA. In one
study a hormonal admixture of ALA was used [65].
The same was noted in animal studies with different
purposes [10,56,63,64,67-72] when the doses used were
described as percentage [63] to doses described as mg/rat
[68] or described as mg/kg which ranged from 20 to
100 mg/kg [10,69,70,72]. As observed in in vitro studies,
most of the in vivo studies did not give an information
about which type of ALA was used. The above-mentioned
events could have resulted in protective or deleterious
actions of ALA upon different cells as recently pointed
out [59]. All these informations must be considered in
relation to the absorption rate of the usual prescribed dose
of 600 mg which reachs a plasmatic peak of 4 ug/ml,
that corresponds to a plasmatic concentration of 0.0194
mmol/L, in about 30 minutes after its ingestion.
Clinical use of ALA in conditions other than diabetes
Brain diseases and cognitive dysfunction
Brain is considered to be one of the major glucose and
oxygen consumer organs, although it corresponds to only
2% of the total body weight [73]. Neurons and astrocytes
are the most active cells of neurometabolism and are con-
sidered to be the neurometabolic couple. Currently, oxida-
tive stress, an imbalance between the production of ROS
and the antioxidant defenses plays an important function
in the occurrence of neurodegenerative diseases as well in
brain injuries, mediated mainly by mitochondrial dysfunc-
tion [14,64,74]. Moreover, the brain has a great sensitivity
to oxidative stress-induced damage [75]. Considering ALA
as an antioxidant compound its use has been reported in
some brain diseases and associated with cognitive dys-
function such as Down syndrome [15] and AD [76,77].
In a randomized, double blind placebo- controlled
study in patients with Down Syndrome with pre-dementia,
the use of 900 UI of alpha-tocopherol plus 200 mg of
ascorbic acid and 600 mg of ALA for two years did not
show improvement in cognitive dysfunction or stabilization
of cognitive decline [15]. It is well known that these patients
are at an increase risk in developing AD, and oxidative
stress is considered to be an important feature of the Down
syndrome.
In AD, ALA in association with n-acetylcysteine has
shown to have a protective effect upon oxidative stress
in fibroblasts decreasing caspase proteins which were
responsible for apoptotic processes in patients with AD
[14]. In a triple transgenic animal model of AD, ALA
was able to improve neurons plasticity and improve
many pathways of insulin signaling in the brain similar
to the action described with metformin [77,78]. So far,
only two clinical studies have addressed the use of ALA
(600 mg/daily) in patients with AD, both studies wereopen-labeled [79,80]. One study was conducted with nine
patients followed by 12 months [79] and the other with 43
patients followed by 24 months [68], both showing a slow-
ing in the disease progression. Meanwhile, when ALA was
associated with exercise training in animal model an in-
crease in some antioxidant enzymes were observed [81].
Obesity
The increasing prevalence of obesity worldwide is an im-
portant epidemiological issue because it is occurring in
parallel with the increase in the prevalence of DM and
cardiovascular disease (CVD). Moreover, it is well known
that both conditions are associated with insulin resistance,
an increased plasmatic level of free fatty acids, of pro-
inflammatory cytokines such as tumor necrosis factor
alfa (TNF-α), interleukin 6 (IL-6) and decreased levels
of adiponectin which is considered to be a protective
cytokine [65,82,83]. The above-mentioned mechanisms
seem to be related to oxidative stress and activation of
NfKB [84]. ALA has many actions that may result in
weight loss such as activation of AMPK in peripheral
and brain tissue [59], inhibition of NfKB [44] and adipo-
cyte differentiation [65]. Animal studies showed that rats
fed with a high fat diet with ALA supplementation had
less weight gain and better plasmatic lipid profile than the
control group [65]. Some of these effects, such as the
increase in HDL-cholesterol and the decrease in LDL-
cholesterol levels were dose dependent. Some studies
suggest that the ability of ALA supplementation in pre-
venting insulin resistance might be related in part to the
stimulation of AMPK and adiponectin in white adipose
tissue [82] and attenuation of monocyte chemokine pro-
tein 1 (MCP-1) and TNF-α [71]. The authors suggested
that ALA may modulate visceral adipose inflammation.
Data from human studies have shown conflicting re-
sults related to lipid metabolism [8,85-88]. Considering
weight loss, the studies have used doses of ALA ranging
from 1,000 mg to 1,800 mg for up 20 weeks in obese
patients with or without glucose intolerance and have
shown a weight loss around 3 kg [8,87,88], that corresponds
to a 3% of weight loss [87]. It is important to emphasize
that the use of sibutramine for one year at a constant dose
of 15 mg/daily resulted in a weight loss of about 7% [89].
However, in obese glucose intolerant subjects ALA has only
shown an increase in LDL-oxidation in comparison to
subjects who completed 12 weeks of ALA used associated
with exercise [8]. Another study did not show any advan-
tage of ALA supplementation for two weeks over lipid-
induced insulin resistance in obese or overweight subjects
[85]. However, an intravenous treatment with 600mg
of ALA for two weeks in obese patients with glucose
intolerance resulted in improvement of insulin resistance,
decreased levels of free fatty acids, LDL-cholesterol as well
oxidized LDL, TNF α and IL-6 [86].
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open-label pilot trial in patients with schizophrenia with-
out DM taking atypical antipsychotic drugs showed a
weight loss of −2.2 kg ± 2.5 kg. The weight loss was
greater in patients taking antihistaminic antipsychotic
agents, mainly clozapine, olanzapine or quetiapine [88].
Further studies are necessary to address the clinical
use of ALA as anti-obesity drug with more complete
data about dietary habits including the ingestion of fruits
and vegetables which are the main source of antioxidants
in a regular diet.
Nonalcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is considered
the most prevalent liver disease worldwide. NAFLD is
frequently associated with metabolic syndrome, obesity,
DM and dyslipidemia [90]. During the natural history of
NAFLD up to 25% of the patients developed non-alcoholic
steatohepatites (NASH) [91]. Currently, mitochondria
dysfunction, oxidative stress and inflammation play a
key role in the pathogenesis of NAFLD and NASH [55].
Some animal studies have brought to light the possible
mechanisms involved in the action of ALA in NAFLD
and NASH in the last years [92,93]. In one study, the use
of ALA was followed by improvement in serum levels of
insulin, free fatty acids, glucose, IL-6, triglycerides and
markers of inflammation and of innate immune activation
(Toll-like receptor 4, TLR4) in liver biopsy [93]. Two other
studies using animals fed with a high fat diet showed that
ALA induced an increase in uncoupling protein 2 which
inhibits electron transport chain resulting in decreased
ATP and lipid synthesis [92]. Moreover this action on
mitochondria efficiency seems to be related to an in-
creased action of the sirtuin proteins [94]. These proteins
have many actions in several intracellular pathways associ-
ated with antioxidant defense [95,96].
Burning mouth syndrome
Burning mouth syndrome (BMS) is a chronic disease
characterized by pain, burning and itching of the oral
cavity without association to any systemic disease. Some-
times xerostomia and dysgeusia could be present [97].
BMS is more prevalent in women in the menopause
period. In Brazil its prevalence is of 1% [98]. The etiology
is probably multifatorial including psychiatric diseases and
hypothyroidism [99]. ALA was used during two months
in patients with BMS in a dose of 600 mg daily but with
conflicting results [98-100].
Cardiovascular disease and endothelial function
The main cause of mortality in non diabetic as well as
in diabetic subjects worldwide is CVD [101]. CVD is
multifactorial being the oxidative stress and a pro-
inflammatory state considered to be the most importantmechanisms involved in the large spectrum of CVD
[102]. In this setting, ALA which has antioxidant as well
anti-inflammatory actions has been used in several stud-
ies, both animal [8-10,68-70] and human [9,103] address-
ing different aspects of CVD.
For instance, the acute use of ALA in a 600 mg dose,
associated with 1,000 mg of vitamin C and 600 IU of
Vitamin E was able to ameliorate markers of oxidative
stress and endothelial dysfunction evaluated by flow-
mediated vasodilation (FMD) of the brachial artery in the
elderly [7]. The effects of ALA upon endothelial function
and markers of oxidative stress were age dependent and it
was not observed in young subjects. In contrast, a review
of many clinical trials using chronic antioxidant therapy
was not able to demonstrate benefits on CVD [103].
In animal models, those fed with a high cholesterol
diet, the use of ALA for 12 weeks reduced oxidative
stress and weight and improved vascular reactivity [10].
Moreover, a reduction in the wall volume of abdominal
aorta with slowing rate of the plaque progression and a
reduction of the expression of adhesion molecules in
thoracic aorta were also observed. One important finding
in this study was the demonstration that ALA decreased
the activation of NfKB which regulates the expression of
pro-inflammatory genes as well adhesion molecules [10].
The effects and mechanisms of ALA on myocardial in-
farct size and diabetic cardiomyopathy which is defined
as a ventricular dysfunction in diabetic patients without
any other cause, were also evaluated in animal studies
[66,67]. Cardiac fibrosis which is the main feature of car-
diomyopathy, was investigated in animal with streptozo-
tocin (STZ) DM-induced [66]. In these animals the use
of ALA had different actions such as improvement of
cardiac function and cardiac fibrosis. Analyzing the left
ventricular sections of these animals it was observed a
better oxidative stress profile and a decreased expression
of transforming growth factor β and smooth muscle
actin, both associated with collagen production.
In animal models of ischemia-reperfusion it was dem-
onstrated that ALA ameliorates cardiac dysfunction with
a decrease in the infarct size, TNF-α, mieloperoxidase,
markers of cell death (lactate dehydrogenase and creatin-
ine kinase), and upregulates gene expression of several
antioxidant enzymes [67]. The mechanisms of action of
ALA were related to the phosphorylation of PI3K/AKT
without any effect on nitric oxide production. Addition-
ally, all these actions were dose dependent, being the dose
of 15mg/kg the most effective. No effects with lower or
higher doses were observed [67].
A benefit obtained with the use of ALA in hypertension
was described and could be related to oxidative stress as
well as to the modulation of intracellular Ca2+ [3]. In
animal studies of glucocorticoid-induced hyperten-
sion, the use of ALA prevented only dexamethasone
Gomes and Negrato Diabetology & Metabolic Syndrome 2014, 6:80 Page 7 of 18
http://www.dmsjournal.com/content/6/1/80induced-hypertension [65]. In human studies the use
of ALA as a hypotensive agent presented conflicting
results showing improvement or no effect [52,104].
For instance, the Island Study which used ALA (300 mg/
d) plus irbesartan (150 mg/d) for 4 weeks in subjects with
metabolic syndrome did not find any difference in blood
pressure albeit an improvement in flow mediated vasodila-
tion and a reduction in plasma levels of IL-6 and 8-
isoprostane [52]. Moreover it was also demonstrated that
both drugs had a synergistic effect upon markers of endo-
thelial dysfunction, inflammation and oxidative stress. It is
important to emphasize that this study was not designed
to evaluate blood pressure and the dose used of ALA was
lower than the doses that are usually employed.
Cancer
Oxidative stress plays an important role in tumorigenesis
[105]. ALA has been used as an anticancer agent mainly
in experimental studies of different tumorigenesis cells
type with promising results [16,106-110]. So far the
exact molecular mechanisms involved in this action
are unknown. Besides its antioxidant acitivity, another
possibility could be its relation to the capacity of inducing
cellular apoptosis as recently demonstrated in lung cells
[106]. This effects may result from activation of caspases
proteins induced by endoplasmic reticulum stress [109].
Another hypothesis is associated with the metabolism of
cancer cells which convert preferentially glucose to lactate,
a mechanism known as the Warburg effect [108]. ALA is
the cofactor of pyruvate deydrogenase which converts
pyruvate to acetil CoA resulting in a decrease in the
formation of lactate [107]. The net effect of this action is
the inhibition of glycolysis. Additionally, an inhibition of
mTOR (target of rapamycina), a signaling pathway re-
sponsible for cell growth and related to insulin receptor
phosphorylation- PI3K-AKT activation, has been demon-
strated in assays using insulinoma cells [57]. This action
resulted in an inhibition of insulin secretion and of beta
cells growth [57]. In contrast, recent data have demon-
strated an antiapoptotic action of ALA due to a activation
of PI3-K/AKT [111]. In addition, in this study it was also
showed a direct binding site of ALA to insulin receptor
[111]. It is possible to speculate that ALA can act in alter-
native routes resulting in different effects. The few studies
in humans are case reports [111]. In these studies ALA
was used associated with other antioxidant agents [111] or
with other anticancer drugs [111].
Miscelaneous disorders
ALA has been used in other clinical conditions such as
glaucoma [72] and osteoporosis [112,113]. Both condi-
tions are associated with an imbalance in the redox state.
In a mouse model of glaucoma the increase in intraocular
pressure was correlated to increased levels of lipidperoxidation and of oxidative stress-related genes expres-
sion in retina. Moreover, in these animals the addition of
ALA to the diet enhanced antioxidant defenses, prevented
retinal ganglion cell losses without significant intraocular
pressure changes.
In a rat model of estrogen deficiency induced by ovari-
ectomy the use of ALA increased bone mineral density
(BMD) and decreased inflammatory markers such as
TNF- α and IL-6. Besides these effects, the use of ALA
also decreased the levels of osteopontin, a protein related
to bone resorption [113]. In a model of low BMD induced
by high-fat diet, which is a potent inducer of oxidative
stress, the ALA supplementation resulted in an increase
of the levels of expression of genes related to antioxidant
enzymes, BMD, and biomarkers of bone formation, such
as osteocalcin, and a down regulation of genes related to
bone resorption activity, like osteoprotegerin, in femur
biopsy. These studies indicated a possible action of ALA
upon maintenance of bone balance.
Clinical use of ALA in diabetes
DM comprehends a group of genetically and clinically
heterogeneous metabolic disorders that are characterized
by hyperglycemia which results from a defective insu-
lin secretion and/or activity [114]. The World Health
Organization (WHO), estimated that by 2025 there will be
300 million people with DM in the world. DM carries a
great risk of morbidity and mortality due to the micro-
vascular and macrovascular complications that can lead to
a lower quality of life and life expectancy [115]. Currently,
these complications can be postponed by achieving ad-
equate glycemic control, as demonstrated by the Diabetes
Control and Complications Trial, the Epidemiology of
Diabetes Interventions and Complications and UKPDS
[116-118]. However in routine clinical practice good gly-
cemic control is very difficult to be achieved [119,120].
The aforementioned diabetes-related complications lead
to a significant burden to the individual and to the society
as a whole [121,122].
The mechanisms underlying the development of DM
related- chronic complications either micro or macro-
vascular are associated to glycemic control [90,116-118].
However, many other factors may contribute or have a
direct relationship with these complications, such as
oxidative stress [123], markers of insulin resistance [124],
markers of low-grade inflammation [125], dyslipidemia
[126], hypertension [126,127] and obesity [127]. Indeed,
DM-related complications may be considered multifactor-
ial as DM itself [114]. In this context, oxidative stress- re-
lated hyperglycemia is considered to be more and more
important in the development of DM as well in the devel-
opment of its related complications [85,102]. This duet,
oxidative stress- related hyperglycemia may induce
modifications in signaling pathways responsible for several
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related to inhibition of insulin signaling pathway resulting
in insulin resistance [128], reduced insulin gene expression
and consequently reduced insulin secretion by beta cells
[129]. Moreover, currently there is compelling evidence
linking this duet to epigenetic modifications resulting in
activation of genetic transcription or repression, silencing
the genetic transcription as recently described [45].
In this study it was shown an increasing expression of
the subunit p65 of NfKB which resulted in increased tran-
scription of vascular cell adhesion.molecule-1 (VCAM-1)
and monocyte chemo attractant molecule-1 (MCP-1)
in human aortic endothelial cells under hyperglycemia
medium [45]. MCP-1 and VCAM are both related to
hyperglycemia-induced arterial pathology. Moreover,
this reaction persisted after a long period of normogly-
cemia establishing the concept of metabolic memory at
molecular level.
Recently it was demonstrated also a downregulation of
LASY in diabetic animals [18]. In this study either treat-
ment with medium with high glucose or TNF-α resulted
in reduction of LASY mRNA [18]. Moreover, a knockout
of LAISY showed an intracellular decrease in GSH,
superoxide dismutase (SOD) and catalase and an increase
in superoxide anion resulting in activation of NfKB, Add-
ing ALA in the cellular medium an up-regulation of
LAISY expression was observed [18].
Another important factor in the pathogenesis of diabetes-
related complications is the formation of advanced gly-
cation end-products (AGEs) which are derived from
intracellular glucose auto-oxidation and non-enzymatic
reactions between glucose and intracellular and extracellu-
lar proteins [130-133]. AGEs by different mechanisms may
damage target cells located in retina, endothelium and
glomeruli [131]. AGEs/receptor interactions (AGE/RAGE)
may result in altered functions of intra and extracellular
proteins, induction of oxidative stress and modifications of
matrix proteins resulting in modifications of its functional
properties [132]. AGE may also activate PKC which is a
signal transduction pathway for regulating many vascular
functions like blood flow, permeability, basement mem-
brane thickening and the expression of nitric oxide
synthase [133].
Considering the pleiotropic actions of ALA or its re-
duced form, DHLA in many signaling pathways associated
with the pathophysiologic process of DM development
as well as the development of its above mentioned
chronic-related complications, its use as a therapeutic
agent sounds promising.
Use of ALA in diabetes treatment
ALA has been used in 94 patients with T2M in a random-
ized, double-blind placebo-controlled study which has
tested three antioxidants for three months in associationwith metformin and glimeperide: ALA, 300 mg/daily,
ecosapentanoic acid, 180 mg plus docohexaenoic acid,
120 mg/daily [omega 3 fatty acids] and vitamin E
400 mg/daily [134]. Although an improvement in HbA1c,
weight and waist have been observed with ALA, omega 3
fatty acids gave the better results concerning weight loss
and glycemic control [134].
Another randomized, placebo-controlled study with 38
patients treated with different doses of ALA (ranging from
300 to 1200 mg/daily), for six months, showed a decrease
in HbA1c and fasting blood glucose in the group random-
ized to ALA [135]. However, there was only a statistical sig-
nificant difference only with the pooled group of ALA. The
reduction of HbA1c was ALA dose-dependent. Moreover,
markers of oxidative stress such as lipid peroxidation
and oxidative damage of DNA did not show any modi-
fication. Another randomized, double blind placebo-
controlled study involving 102 patients treated with ALA
(600 mg/daily), ALA 600 mg/daily plus 800 mg/daily of α-
tocopherol daily for four months showed improvement in
some lipid fractions and glucose in the ALA group and
ALA plus α-tocopherol but without statistical significance
[136]. Data obtained in clinical studies using ALA in the
treatment of diabetes-related complications are summa-
rized in Table 2.
Use of ALA in diabetes-related chronic complications
Use of ALA in diabetic retinopathy
ALA has been used to evaluate retinal mitochondria
biogenesis in rats in a model of reinstitution of good
control after six months of poor metabolic control
[137]. In animals without ALA supplementation and
under poor glycemic control it was observed a dysreg-
ulation of retinal mitochondria biogenesis with a de-
creased expression of citrase synthase (a marker of
mitochondria functional integrity), a decreased number of
mitochondria and an increased number of acellular ca-
pillaries (a marker of diabetic retinopathy). Moreover,
in this study the supplementation of ALA in animals
soon after induction of DM prevented most of the
above-mentioned alterations [137]. In another experi-
mental study, the treatment with ALA in diabetic ani-
mals reduced the markers of oxidative stress, NfKB
activation and vascular endothelial growth factor in
diabetic retina [138].
A randomized, double-blind placebo-controlled study
with 235 patients with T2D and 170 patients with type 1
diabetes (T1D) patients using ALA 600 mg/daily for 2
years (96 weeks) did not show any kind of prevention
upon the development of diabetic macular edema [139].
However, using ALA (400 mg/daly) in combination with
other anti-oxidants (genistein and vitamins) in 32 dia-
betic patients an improvement in electroretinogram
was observed after 30 days of treatment [140].
Table 2 Clinical studies with ALA in patients with diabetes





Type 2 diabetes treatment
Udupa, AS [134] Randomized, double-
blind placebo-controlled
Vitamin E, omega 3
fatty acids ALA
300 mg All of them
daily/orally
Weight, waist glucose 104 with IR 5-10 y 12 w < HbA1c, weight, waist Better
results with omega-3 followed
by vitamin E and ALA
Porasuphatana S [135] Randomized, placebo-
controlled
ALA 300 mg -1200
mg/d
HbA1c, FBG 38 2.07 ± 0.26 24 w <HbA1c, FBG
De Oliveira AM [136] Randomized, double-
blind placebo-controlled
ALA 600 mg or
Vitamin E 800 mg or
ALA 600 mg plus





Haritoglou C [139] Randomized ,double-blind
placebo-controlled
ALA 600 mg/daily Development of
macular edema
232 patients with
type 2 and 170 with
T1D
86 w no effect
Nebioso M [140] Randomized not
placebo-controlled
ALA 400 mg daily
plus vitamins and
genistein
ERG 32 NA 4 w Improvement in ERG
Diabetic nephropathy
Borcea V [143] Cross-sectional not
placebo-controlled
ALA 600 mg/daily/orally Lipid ROOH, HbA1c,
urine albumin, α
tocopherol
107 patients [45 with
T1D and 29 with T2D]
21.7 ± 11.1 (with
ALA); 15.3 ± 10.4
(without ALA)
>12 w < ROOH < ROOH/(,α tocopherol/
cholesterol The decrease was
independent of HbA1c and
urine albumin level
Cicek M [144] Randomized not
placebo-controlled
ALA 600 mg/ /orally CIN Plasma creatinine,
Cystation C
79 NA Prior coronary
angiography
No effect in the incidence of CIN,
creatinine, Cystatin C pré /pos
exam
Chang JW [145] Randomized
placebo-controlled





NA 12 w Decrease the level of ADMA
Diabetes endothelial dysfunction
Heinisch BB [147] Randomized, Controlled,
double- blind placebo
parallel






30 patients with TD2 7 ± 6 3 w Improvement in endothelium
dependent function
Diabetic cardiovascular autonomic neuropathy
Pop-Busui R [150] Prospective, randomized,
double- blind,
placebo- controlled
ALA 600 mg/twice daily
Nicotinamide 750 mg/
twice daily Allupurinol
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73 patients with T2D 15.3 ± 8.3 16 w Improvement on root mean square
successive difference and power
spectrum in low frequency band







ALA:1200 or 600 or
100 mg/daily
(orally)
TSS HbA1c 328 patients with T2D
with symptomatic
peripheral neuropathy










299 patients (T1D and
T2D) with symptomatic
polyneuropathy
NA 2 y Improvement in electrophysiological





ALA 600 mg/ IV
followed by 1800 mg
of ALA or placebo
orally
TSS NIS 516 patients with T2D
with symptomatic
polyneuropathy
11 3 w (IV) 24 w
(orally)






ALA 600 mg IV TSS 120 (T1D and T2D)
with DSPN
















ALA 600 mg/orally TSS Composite score
( NIS–lower limbs plus
7 neurophisiologic
tests (NIS-LL+7)
460 (T1D and T2D)
with DSPN
13.3 4 years TSS: no improvement NSI-LL+7:
improvement
Ziegler D [160] Meta-analysis ALA 600mg IV TSS, NIS-LL 1258 132 months 3 w Improvement in TSS (papin-prick,
touch-pressure), burning,numbness)
Improvement in NIS-LL
Mijnhout GS [161] Meta-analysis ALA orally ( 600 to
1800 mg daily) ALA IV
(100 to 1200 mg/daily)
TSS 653 NA 3 to 5 w Improvement in TSS but greater
than 30% only in intravenously
treated patients
ALA, alpha-lipoic acid; w, weeks; y, years; IV, intravenously; HbA1c, glycated hemoglobin; FBG, fasting blood glucose; HOMA index, homeostasis model assessment; ERG, electroretinogram; ROOH, hidroxiperoxides;
CIN, contrast induced nephropathy; ADMA, asymmetric dimethyl-arginine; PET, positron emission tomography; TSS, total symptoms score; NIS, neurophaty impairment score; NIS-LL, neuropathy improvement score of
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The effects of ALA in the development of diabetic
nephropathy was investigated mainly in animal studies.
In diabetic animal strepzotocin (STZ)-induced DM
and apolipoprotein deficient fed high fat diet the pro-
tective effect of ALA supplementation was evaluated in
three different time schedule : pre-STZ, simultaneously
and pos-STZ. No statistical difference was noted among
the groups concerning hyperglycemia, although an at-
tenuation of hyperglycemia was observed in the group
pre-STZ. Analyzing the pooled group it was found a
reduction in IL-6, urine albumin, urine isoprostane
and an increase in erythrocyte GSH in the group under
ALA supplementation. The decreased gene expression
of superoxide dismutase in diabetic animals was normal-
ized with ALA. Two other animal studies showed interest-
ing data [141,142]. One study showed that LASY-deficient
animals present reduction in antioxidant defense. More-
over, in this study it was also found an overproduction of
superoxide in the proximal tubular cells which could
be an important event for accelerating the development of
diabetic nephropathy [141]. Another study showed op-
posite action of ALA in animals with STZ-induced DM.
In diabetic animals ALA decreased urinary albumin and
markers of oxidative stress, but in non-diabetic animals
pro-oxidant effects were observed with an increase in
urinary albumin, creatinine and markers of oxidative
stress [142]. This effect may be at least partially ex-
plained by the high dose used in the experiment.
So far, the few human studies which have been done
had different objectives [143-145]. One cross-sectional
not placebo controlled study using 600 mg/daily of ALA
for more than three months in 107 patients with T2D
and T1D showed a reduction of lipid hydroxiperoxides.
Moreover this reduction was independent of the level of
HbA1c and urine albumin [143].
The protective effect of ALA on the development of
contrast-induced nephropathy (CIN) was evaluated in 68
patients with DM undergoing coronary angiography.
The patients received 600 mg of TA prior to the pro-
cedure or no treatment (control group). The two
groups had the same incidence of CIN, 8%, without dif-
ference in the plasma levels of creatinine, cystatin C
pre/pos procedure [144]. The effect of ALA upon
asymmetric dimetihylarginine (ADMA) which is an in-
hibitor of nitric oxid synthase, was investigated in a
randomized, control study for 12 week in 50 diabetic
patients undergoing hemodyalisis. ALA, 600 mg/daily
decreased the levels of ADMA without difference in
the other analyzed parameters [145]. An open and
non-randomized exploratory study, investigated the
effect of 600 mg/daily of ALA for 72 weeks on urinary
albumin excretion and plasma levels of trombomodulin in
patients with T1D and T2D. A decrease in the level oftrombomodulin and no changes in the urinary albumin
were observed in the treatment group [146].
Use of ALA in endothelial dysfunction
A randomized, controlled, double blind, parallel study
with 30 patients with T2D evaluated glycemic control
and endothelial responses to intravenous acetylcholine
(endothelium dependent) and nitrate (endothelium inde-
pendent) in order to evaluate the forearm blood flow
before and after the use of 600 mg of ALA intravenously
for three weeks [147]. A decrease in HbA1c, total chol-
esterol and triglycerides levels were observed in both
groups. However only the patients ALA treated showed
an improvement in the endothelium dependent vaso-
dilation. ALA or placebo did not influence endothelium
independent vasodilation [147].
Use of ALA in diabetic wound healing
An experimental study in vitro and in vivo has demon-
strated a possible benefit of topical application of ALA
alone or in combination with other anti-oxidant agents for
diabetic wound healing [148]. In this study the expression
of RAGE was attenuated in skin wound in diabetic ani-
mals when ALA was used in combination with other
anti-oxidants agents for one week. Moreover, the use
of ALA in combination with other anti-oxidants agents
accelerated the skin wound healing with increased expres-
sion of vascular endothelial growth factor (VEGF) in the
wound area.
Use of ALA in diabetic cardiovascular neuropathy
Cardiovascular autonomic neuropathy was evaluated
in two human studies. One, randomized, double blind,
placebo controlled multicenter study (DEKAN) was
conducted in patients with T2D with cardiovascular auto-
nomic neuropathy (CAN) using 800 mg of ALA daily for
16 weeks [149]. Autonomic symptoms and heart rate vari-
ability were evaluated before and after the intervention.
The intervention with ALA resulted in improvement of
some parameters of heart rate variability analysis: root
mean square successive difference and power spectrum in
low frequency band. No difference was observed in overall
symptoms. Another study, a prospective, randomized,
double blind, placebo controlled study was performed
in 44 patients with T1D presenting any diabetes-related
chronic complication (mild non-proliferative retinopathy
or microalbuminuria and the presence of cardiac auto-
nomic neuropathy (CAN) defined by an alteration of posi-
tron emission tomography (PET) with normal autonomic
reflex testing [150]. Patients were submitted to triple
anti-oxidant therapy with the objective to target differ-
ent pathways of oxidative stress damage: inhibition of
xantina-oxidase by allopurinol 300 mg/daily, inhibition of
oxidative stress by ALA, 600 mg/twice daily and inhibition
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was found in all parameters of autonomic function
analysis as well as in urinary levels of isoprostanes, a
marker of oxidative stress. Meanwhile a detrimental
effect in some regions of left ventricle was observed in
PET analysis [150].
Use of ALA in diabetic neuropathy
So far, the majority of clinical studies using ALA thera-
peutically were conducted in order to evaluate its action
on diabetic neuropathy. The earlier studies were performed
between 1980/1993. In general these studies were uncon-
trolled, double/single blind or open label, including few
patients, had short duration and used a wide range dose
either orally or intravenous [11]. The main benefit of ALA
was an improvement of symptoms and in distal motor
never latencies. It is beyond the scope of this review to
analyze each of these studies but they did not have a defin-
ite conclusion about the effects of ALA upon diabetic
neuropathy. However they have given key information
about how to perform other clinical trials better designed
to in order to evaluate this topic. It is important to
emphasize that at this time the lack of standardization of
definition as well as standard criteria for diagnosing dia-
betic neuropathy are unsolved problems due to different
worldwide consensus in the subject. These consensuses
have established scores like Neuropathy Symptoms Score
(NSS), Total Symptoms Score (TSS), and Neuropathy Im-
pairment Score (NIS) [139,151,152] which addressed the
intensity and frequency of the most important symptoms
of diabetic neuropathy such as pain, burning, numbness
and paresthesias. The above-mentioned scores facilitated a
normatization of the outcomes in these clinical trials after
the 1990’s [153-159]. The first of these studies was the
ALADIN (Alpha Lipoic Acid in Diabetic Neuropathy)
which was designed to evaluate the efficacy and safety of
intravenous ALA during three weeks in three different
doses, 1200 mg, 600 mg and 100 mg in comparison to
placebo in 328 patients with T2D with symptomatic distal
symmetric diabetic polineuropathy (DSPN) [153]. In this
study an improvement in TSS was noted in the group
using 600 mg vs placebo establishing the safety and efficacy
of this dose in comparison to the 1200 mg dose. Moreover,
at the dose of 1200 mg a higher rate of adverse events were
observed mainly in the gastrointestinal tract. No difference
in HbA1c was observed at the end of the study which
included 260 patients. This study was followed by
ALADIN II which was a long-term trial (24 months)
that addressed also electrophysiological tests and Neur-
opathy Disability Score (NDS) using the same doses of
ALA but orally in 299 patients with T2D. In this study
only 65 patients could be included in the final analysis be-
cause the variability in the electrophysiological tests biased
the final results [154]. Although some improvement insensory nerve function was noted the excessive number of
patients excluded should be considered when interpreting
these results. The ALADIN III Study has combined
600 mg of ALA intravenously for three weeks followed
either by 600 mg of ALA three times daily or placebo
for six months (24 weeks) [155]. No improvement in
TSS and NIS were observed at the end of the study,
although some analyzed parameters such as NIS and
TSS presented positive results in short period of ALA
intravenously administration (tree weeks). Moreover, a high
rate of dropout was noted (about 25%). Recently three
randomized, double blind, controlled parallel studies were
concluded addressing the efficacy and safety of ALA in
diabetic patients with DSPN with TSS or NIS as primary
outcome. The majority of the included patients had T2D
(up to 70%) [156]. The SYDNEY Trial, a monocenter,
short-term study used ALA intravenously during five days
a week for three weeks and showed improvement in TSS
[157]. The SIDNEY 2 Trial was a multicenter study which
used doses of ALA ranging from 600 to 1800 mg daily and
also showed an improvement in TSS [158]. Finally, it is
important to mention the NATHAN 1 Trial (Neurological
Assessment of Thioctic Acid in Diabetic Neuropathy), a
multicenter study which used 600 mg of ALA daily for four
years with NIS-Lower Limb + seven neurophysiologic tests
as primary outcome. In this study after a four-year treat-
ment with ALA in mild-to-moderate DSPN did not influ-
ence the primary composite end point but resulted in a
significant clinical improvement and prevention of progres-
sion of neuropathic impairments. As the primary composite
end point did not deteriorate in placebo-treated subjects,
secondary prevention of its progression by ALA according
to the trial design was not feasible [159]. All these latter
studies concluded that the usual dose of 600 mg has efficacy
and safety and adverse events, mainly in the gastrointestinal
tract, that were dose dependent. Moreover, with one
exception (sural latency), all these studies did observe
improvement in electrophysiological tests.
Two recent meta-analysis evaluate the use of ALA in
diabetic neuropathy [160,161]. One, included 1,258 dia-
betic patients treated with 600 mg of ALA, intravenously
for three weeks, concluded that individualized TTS such
as pain, numbness and burning decreased significantly
with ALA in comparison to placebo. Considering the
components of NIS-LL an improvement was noted in
pin-prick, touch pressure and ankle reflexes [160]. This
meta-analysis also pointed out some relevant aspects for
conducting future trials to evaluate the benefits of ALA
on diabetic neuropathy as follows: homogeneity of the
studied patients; duration of the trial; end-points with
less variability and finally considering the slowing pro-
gression of diabetic neuropathy the end point must
have to exclude the latter and address improvement.
The other meta-analysis included 653 diabetic patients
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or intravenously (two studies) for three (3 studies) to 5
weeks (one study) concluded that TSS decreased sig-
nificantly but only in the intravenously study the TSS
decrease more than 30% which was considered to be clin-
ically significant [161]. Recently, a non-randomized, open-
label and prospective study has shown an improvement in
pain and eletroneurographic parameters, mainly in sen-
sory nerve conduction, in 50 patients with diabetes and
symmetric sensorimotor polyneuropathy treated with a
new oral formulation combining ALA 400 mg/daily and
superoxide dismutase 140 IU/daily for four months [162].
Recently, a randomized, open label, parallel study
showed no benefit of adding methylcobalamine(750 ug)
and ALA(100 mg) to pregabalin (75 mg) for 12 weeks in
parameters of nerve function and pain evaluation [163].
Another prospective, observational study showed that
after 21 months patients using pregabalin had better
improvement in symptoms of diabetic neuropathy in
comparison to patients using either carbamazepine and
ALA [164].
Adverse events
Adverse events related to the administration of ALA
were described mainly in clinical trials [153,158,159] but
generally without difference when compared with placebo.
The majority of these adverse events were dose-dependent
and in the gastrointestinal tract (nausea, vomiting, dys-
pepsia and abdominal pain). However other events
were also described like pruritus, bronchitis and skin
ulceration. Recently it was described a case of insulin
autoimmune syndrome probably associated with the
use of ALA as a nutritional supplement [165].
Conclusions
ALA a natural anti-oxidant is a cofactor of mitochondrial
enzymes of oxidative metabolism like pyruvate de-
hydrogenase which link glycolysis to citric acid cycle,
and α-keto-glutarate dehydrogenase. ALA and its reduced
form DHLA have many biological functions in different
intracellular systems resulting in a wide range of actions
such as antioxidant protection, chelation of metal ions,
regeneration of other antioxidant agents such as vitamin
C, E and glutathione. Moreover, ALA/DHLA can also act
in multiple signaling transduction pathways, like insulin,
nuclear factor kappa B (NFkB), nitric oxide synthesis and
cellular apoptosis. Also, ALA/DHLA can modulate dir-
ectly or indirectly the expression of protein kinase C and
AMPK that are both key enzymes in many downstream
systems. All the aforementioned described actions confer
some properties to ALA/DHLA that are not just related
to its reactive oxygen and nitrogen species scavenger but
also to glucose disposal, inflammation, tumorigenesis,
endothelial function, appetite regulation and cognitivefunction. To date, the majority of these actions have been
addressed mainly in experimental studies which used a
wide range dose of ALA in vitro as well as in vivo. We can
also consider that for instance, the used dose was greater
than the physiological dose reached with the usual clinic-
ally used oral dose of ALA. It is also to be mentioned that
in most of these studies it was not well defined which type
of ALA has been used. Finally, the translation of all these
pooled experimental data to human studies is a subject for
further research.
Perspectives
Currently, there are compelling evidences linking oxi-
dative damage to the majority of chronic diseases with
increasing prevalence worldwide such as obesity, DM,
CVD and AD. Considering the pleiotropic action of ALA
upon different pathways associated with the above men-
tioned diseases, its use as a potential therapeutical agent
seems promising. So far, although in a limited number,
the majority of clinical studies, performed in random-
ized double-blind and placebo-controlled ways, have
been done in diabetic patients with DSPN. Future
clinical studies, also randomized double-blind and
placebo-controlled with adequate sample calculation,
homogeneity of the studied patients, longer duration
and a minimal variability in the established outcomes
are needed in order to asses the benefit of ALA upon
other diabetes-related chronic complications. Consid-
ering the latter statement it will be an important issue
to define the use of ALA as primary or secondary
therapeutic intervention. Also, the same aforemen-
tioned type of studies with the same criteria must be
addressed in other clinical conditions such as obesity,
CVD and AD. Another important question to be an-
swered by these clinical studies is when we are going
to start its use according to the natural evolution of
each disease in order to reach a benefit. We need also
more experimental studies to evaluate and define if the
pro-oxidant action of ALA is dose-dependent. These
studies may also give us more information about the
use of lipoic acid synthase as a molecular target for
increasing the mitochondrial levels of ALA. Another
point to be addressed in these studies is the possibility that
hyperglycemia can affect different pathways resulting in a
toxicity which could be independent of oxidative stress
as recently discussed [166]. The role of endoplasmic
reticulum stress has been pointed out as an important
mechanism leading to diabetes-related complications
which is independent of oxidative stress.
Finally, although our review had the objective to ex-
tended our clinical and biological knowledge about ALA
we still need more information about this multifunc-
tional compound to spread its use in routine clinical
practice.
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